<DOC>
	<DOCNO>NCT00022282</DOCNO>
	<brief_summary>RATIONALE : AE-941 may help slow growth multiple myeloma . PURPOSE : Phase II trial study effectiveness neovastat treat patient relapsed refractory multiple myeloma .</brief_summary>
	<brief_title>AE-941 Treating Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Determine confirm tumor response rate patient early relapse refractory multiple myeloma treat AE-941 ( Neovastat ) . - Determine safety drug patient . - Evaluate time progression patient treat drug . - Evaluate duration tumor response ( partial response , response , complete response ) patient treat drug . OUTLINE : This multicenter , open-label study . Patients receive oral AE-941 ( Neovastat ) twice daily . Patients follow every 4 week disease progression . PROJECTED ACCRUAL : A total 125 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis multiple myeloma ( MM ) accord Durie Salmon criterion Refractory early relapse standard chemotherapy without stem cell transplantation Measurable disease Quantifiable IgM , IgG , IgA paraprotein serum AND/OR BenceJones protein urine No plasma cell leukemia ( 20 % plasma cell peripheral blood absolute plasma cell count least 2,000/mm3 ) No nonsecretory MM No spinal cord compression PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : More 6 month Hematopoietic : No clinical symptom hyperviscosity Hepatic : Not specify Renal : Creatinine great 2 time upper limit normal Calcium great 11 mg/dL Other : No prior malignancy within past 5 year except basal cell carcinoma skin carcinoma situ cervix No severe allergy fish seafood No medical condition would interfere intake and/or absorption study medication ( e.g. , gastrectomy major intestinal resection ) No significant medical psychiatric condition would preclude study participation Not pregnant Negative pregnancy test Fertile patient must use adequate contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior history treatment thalidomide 14 day duration At least 4 week since prior biological therapy MM Concurrent epoetin alfa allow Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy MM Endocrine therapy : At least 4 week since prior steroid therapy MM No prednisone maintenance therapy Radiotherapy : At least 4 week since prior radiotherapy No concurrent palliative curative radiotherapy Surgery : Not specify Other : At least 28 day since prior shark cartilage product At least 28 day since prior experimental therapeutic agent Concurrent monthly bisphosphonate ( pamidronates ) infusion allow No concurrent anticancer treatment No concurrent shark cartilage product No concurrent therapy MM</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>refractory multiple myeloma</keyword>
</DOC>